Exceptional response to rechallenge of BRAF/MEK inhibitors in patients with primary acquired resistance to targeted therapy

Схожие документы

• Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy
  по: Caitlyn N. Myrdal, и др.
  Опубликовано: (2020-01-01)
• Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?
  по: Anna Stagno, и др.
  Опубликовано: (2021-05-01)
• Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
  по: Jessie Villanueva, и др.
  Опубликовано: (2013-09-01)
• Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma
  по: Jordan Phillipps, и др.
  Опубликовано: (2024-09-01)
• Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors
  по: Lovisa Falkman, и др.
  Опубликовано: (2024-04-01)